Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors

NCT05262530 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT05262530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05262530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors
Lead sponsor
BioNTech SE
Phase
Phase 1/2
Overall status
Terminated
Start date
March 22, 2022
Completion date
December 22, 2025
Enrollment
73 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor